- Home
- CNTA
as 11-05-2025 12:00pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 2.3B | IPO Year: | 2021 |
| Target Price: | $31.75 | AVG Volume (30 days): | 859.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.60 - $25.42 | Next Earning Date: | 11-12-2025 |
| Revenue: | $15,000,000 | Revenue Growth: | 118.88% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Accardi Mario Alberto | CNTA | President, Orexin Program | Oct 27 '25 | Sell | $25.00 | 8,000 | $200,000.00 | 194,394 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Oct 15 '25 | Sell | $22.41 | 6,000 | $134,439.00 | 105,386 | |
| Bush Tia L | CNTA | Chief Technology & Quality Ofc | Sep 24 '25 | Sell | $24.00 | 35,000 | $840,000.00 | 121,503 | |
| Accardi Mario Alberto | CNTA | President, Orexin Program | Sep 16 '25 | Sell | $21.68 | 8,172 | $174,846.22 | 194,394 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Sep 15 '25 | Sell | $21.85 | 6,000 | $131,100.60 | 105,386 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Sep 10 '25 | Sell | $22.00 | 20,000 | $440,000.00 | 105,386 | |
| Bush Tia L | CNTA | Chief Technology & Quality Ofc | Sep 10 '25 | Sell | $22.00 | 25,000 | $550,000.00 | 121,503 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Sep 9 '25 | Sell | $20.01 | 20,000 | $400,102.00 | 105,386 | |
| Bush Tia L | CNTA | Chief Technology & Quality Ofc | Sep 9 '25 | Sell | $20.00 | 24,792 | $495,840.00 | 121,503 | |
| Accardi Mario Alberto | CNTA | President, Orexin Program | Sep 9 '25 | Sell | $20.00 | 7,000 | $140,000.00 | 194,394 |
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
Simply Wall St.
19 days ago
Centessa Pharmaceuticals (CNTA): Reviewing Valuation After 46% Three-Month Share Price Surge
MT Newswires
2 months ago
European Equities Traded in the US as American Depositary Receipts Decline Thursday
Insider Monkey
4 months ago
Centessa Pharmaceuticals Receives FDA Clearance for New Drug ORX142, Initiates Phase 1 Study
Simply Wall St.
4 months ago
Centessa Pharmaceuticals plc's (NASDAQ:CNTA) Intrinsic Value Is Potentially 99% Above Its Share Price
MT Newswires
5 months ago
European Equities Traded in the US as American Depositary Receipts Edge Higher Wednesday
TipRanks
5 months ago
Centessa announces clearance of IND for ORX142
Zacks
5 months ago
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?
MT Newswires
5 months ago
Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders
Compare CNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.